FINWIRES · TerminalLIVE
FINWIRES

HKG:2256

6 stories mentioning HKG:2256Updated 24d ago

Every FINWIRES story that references HKG:2256, newest first.

Asia

Abbisko Unit Wins US FDA IND Clearance for Pan-KRAS Drug Candidate

Abbisko Cayman (HKG:2256) said its subsidiary, Abbisko Therapeutics, received U.S. Food and Drug Administration investigational new drug clearance for ABSK211, according to a Hong Kong bourse filing Monday.ABSK211 is an oral, highly potent and selective small-molecule pan-KRAS inhibitor being developed for the treatment of patients with advanced solid tumors harboring KRAS alterations.Abbisko's shares rose 1% in recent trade.

HKG:2256
Asia

Abbisko Unit Teams Up With AstraZeneca for Lung Cancer Drug Trial

Abbisko Cayman (HKG:2256) said its subsidiary, Abbisko Therapeutics, entered into a strategic collaboration with AstraZeneca to jointly develop a combination therapy for non-small cell lung cancer, according to a Thursday Hong Kong bourse filing.The companies will evaluate Abbisko's oral PD-L1 inhibitor, lumipodlin, in combination with AstraZeneca's Tagrisso in a Phase 1/2 clinical trial involving patients with EGFR-mutated and PD-L1-positive locally advanced or metastatic non-small cell lung cancer.Abbisko will lead the Phase 2 study, while both companies will share responsibility for conducting the clinical trial.

HKG:2256
Asia

Abbisko Therapeutics Enters Drug Discovery, Licensing Deal With Eli Lilly

Abbisko Cayman (HKG:2256) unit Abbisko Therapeutics entered a research and license partnership with Eli Lilly to develop new medicines, according to a Wednesday filing with the Hong Kong bourse.The firm will receive an upfront payment, as well as milestone payments totaling up to $1.9 billion. The company will also received royalties on drugs commercialized as a result of the partnership.

HKG:2256
Asia

Abbisko, Eli Lilly Sign Multi-Target Drug Discovery Deal Worth Up to $1.9 Billion

Abbisko Cayman (HKG:2256) expanded its collaboration with Eli Lilly through a new research and licensing agreement covering multiple drug targets, according to a Wednesday Hong Kong bourse filing.Under the agreement, Abbisko will receive an upfront payment and is eligible for development, regulatory, and commercial milestone payments totaling up to about $1.9 billion, along with tiered royalties on future product sales.The company will conduct drug discovery and early-stage development activities for therapeutic programs selected by Lilly, leveraging its discovery platform and research capabilities.The agreement follows a 2022 collaboration between the companies focused on the discovery, development, and potential commercialization of a novel small-molecule therapy.

HKG:2256
Asia

Abbisko Completes HK$523 Million Share Offering

Abbisko (HKG:2256) completed a HK$522.5 million share offering, according to a Hong Kong bourse filing Tuesday.The drug company's shares fell over 2% in afternoon trade Wednesday.The firm sold 42.9 million shares priced at HK$12.18 each to raise funds for the research and development of cancer and non-cancer drug candidates.The shares represent 5.99% of the company's enlarged share capital.

HKG:2256
Asia

Abbisko Seeks HK$523 Million via Share Offering

Abbisko (HKG:2256) said it was looking to raise nearly HK$523 million via a share offering, according to a Hong Kong bourse filing Tuesday.The firm is seeking investors for 42.9 million shares priced at HK$12.18 each to raise funds for the research and development of cancer and non-cancer drug candidates.The shares represent 6.37% of the company's issued share capital and 5.99% as enlarged by the sale.

HKG:2256

Track with the FINWIRES app suite

FolioX
FolioX
Track HKG:2256 in your portfolio
WheelAI
WheelAI
Analyze HKG:2256 options with the wheel strategy
StockInsider
StockInsider
See market sentiment on HKG:2256